Moderna Soars over 5% on Positive Cancer Therapy Results and Analyst Upgrade

Tiger Newspress01-22

Moderna saw its stock price soar 5.12% in pre-market trading, continuing its strong momentum from the previous session. The surge is driven by positive clinical trial results for Moderna's experimental skin cancer vaccine developed in collaboration with Merck & Co. The Phase 2b study showed that adding Moderna's intismeran autogene to KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits over five years.

Additionally, Bernstein raised Moderna's target price to $35 from $25, reflecting increased confidence in the company's growth trajectory. These developments have fueled investor optimism, leading to the stock's pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101751051?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 17:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101751051","market":"us","top_or_hot":-1,"title":"Moderna Soars over 5% on Positive Cancer Therapy Results and Analyst Upgrade","media":"Tiger Newspress","content":"<html><head></head><body><p><strong><a href=\"https://laohu8.com/S/MRNA\">Moderna</a></strong> saw its stock price soar 5.12% in pre-market trading, continuing its strong momentum from the previous session. The surge is driven by positive clinical trial results for Moderna&#39;s experimental skin cancer vaccine developed in collaboration with Merck &amp; Co. The Phase 2b study showed that adding Moderna&#39;s intismeran autogene to KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits over five years.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/ee9106001efd353ae27ce6002ed65d10\" tg-width=\"876\" tg-height=\"603\"/></p><p>Additionally, Bernstein raised Moderna&#39;s target price to $35 from $25, reflecting increased confidence in the company&#39;s growth trajectory. These developments have fueled investor optimism, leading to the stock&#39;s pre-market rally.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Soars over 5% on Positive Cancer Therapy Results and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Soars over 5% on Positive Cancer Therapy Results and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2026-01-22 17:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><strong><a href=\"https://laohu8.com/S/MRNA\">Moderna</a></strong> saw its stock price soar 5.12% in pre-market trading, continuing its strong momentum from the previous session. The surge is driven by positive clinical trial results for Moderna&#39;s experimental skin cancer vaccine developed in collaboration with Merck &amp; Co. The Phase 2b study showed that adding Moderna&#39;s intismeran autogene to KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits over five years.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/ee9106001efd353ae27ce6002ed65d10\" tg-width=\"876\" tg-height=\"603\"/></p><p>Additionally, Bernstein raised Moderna&#39;s target price to $35 from $25, reflecting increased confidence in the company&#39;s growth trajectory. These developments have fueled investor optimism, leading to the stock&#39;s pre-market rally.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1101751051","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101751051","pubTimestamp":1769075537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Moderna, Inc. (MRNA) saw its stock price soar 5.22% in pre-market trading, continuing its strong momentum from the previous session.The surge is driven by positive clinical trial results for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘前大涨5.22%因癌症治疗结果积极及分析师上调评级","themeId":"e85b7da1ffc48d0eac708765940efa15","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna saw its stock price soar 5.12% in pre-market trading, continuing its strong momentum from the previous session. The surge is driven by positive clinical trial results for Moderna's experimental skin cancer vaccine developed in collaboration with Merck & Co. The Phase 2b study showed that adding Moderna's intismeran autogene to KEYTRUDA significantly reduced the risk of recurrence or death in melanoma patients, with sustained benefits over five years.Additionally, Bernstein raised Moderna's target price to $35 from $25, reflecting increased confidence in the company's growth trajectory. These developments have fueled investor optimism, leading to the stock's pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101751051","isCrawlerRequest":true}